Ru (II) compounds have potential application in photodynamic therapy (PDT). In the current study, two Ru (II) compounds based on the auxiliary ligand 2,2′-bipyridine (bipy) by changing main ligands 5-(2-pyridyl) tetrazole (Hpytz) and di(2H-tetrazol-5-yl) amine (H₂datz) have been successfully synthesized and characterized, [Ru (pytz)(bipy)₂][PF₆] (1) and [Ru(Hdatz)(bipy)₂][PF₆] (2). These compounds can form nanoparticles (NPs) by nano-precipitation. And [Ru(pytz)(bipy)₂][PF₆] NPs with a lower half maximal inhibitory concentration (IC₅₀) of 37 μg/mL on HeLa cells than that of [Ru(Hdatz)(bipy)₂][PF₆] NPs (65 μg/mL). Meanwhile, negligible dark toxicity has been also observed for these NPs even under high concentrations. The results show that [Ru(pytz)(bipy)₂][PF₆] (1) and [Ru(Hdatz)(bipy)₂][PF₆] (2) NPs can inhibit cell proliferation in vitro, and may be potential candidates for photodynamic therapy.

钌（II）化合物在光动力疗法（PDT）中具有潜在的应用。在当前的研究中，通过改变主要配体5-（2-吡啶基）四唑（Hpytz）和二（2H-四唑-5-基），基于辅助配体2,2'-联吡啶（bipy）的两种Ru（II）化合物）胺（H ₂ datz）已成功合成和表征，[Ru（pytz）（bipy）₂ ] [PF ₆ ]（1）和[Ru（Hdatz）（bipy）₂ ] [PF ₆ ]（2）。这些化合物可以通过纳米沉淀形成纳米颗粒（NPs）。并且[Ru（pytz）（bipy）₂ ] [PF ₆ ] NPs的半数最大抑制浓度较低（IC ₅₀）在HeLa细胞上比[Ru（Hdatz）（bipy）₂ ] [PF ₆ ] NPs（65μg/ mL）高37μg / mL。同时，即使在高浓度下，对于这些NP也观察到了可忽略的黑暗毒性。结果表明，[Ru（pytz）（bipy）₂ ] [PF ₆ ]（1）和[Ru（Hdatz）（bipy）₂ ] [PF ₆ ]（2）NPs在体外可以抑制细胞增殖，可能是光动力疗法的潜在候选人。